Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
{{output}}
Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treat... ...
